An exosome platform providing a noninvasive, inexpensive, and robust diagnostic tool.
At NeuroDex, we envision a world where effective and preventative
treatments for Alzheimer's exist.
The pharmaceutical industry has struggled over the past two decades to make headway in the Alzheimer's disease space due to a lack of inexpensive, noninvasive diagnostic tools. We want to bring the power of exosomes to the neurological diagnostic space - our technology has the potential to enable early detection, patient stratification, and disease monitoring, which we believe will enable the first disease-modifying treatment for Alzheimer's.
Our proprietary neuron-derived exosome isolation technology can be applied across a number of neurological indications. With our technology, a simple blood draw could allow physicians and researchers to open a window into the brain.
Our lead indication is Alzheimer's disease, a poorly understood disease affecting a third of the 65+ age population.
Leveraging regulatory FDA framework for Lab- Developed-Tests creates a quick to-market-opportunity
Capturing neuron derived exosomes enables identification of diverse pathological aspects
Use of frozen samples enables utilization of retrospective biobanks
Our data demonstrates a robust and high precision platform
We offer an isolation platform that can be combined with different detection methodologies
We have industry and academic experience in public and private diagnostic companies
Dr. Eitan was the first to study exosome...
Oded is an experienced diagnostics execu...
Christina is a Certified Public Account...
PUBLICATIONS FROM OUR TEAM
Please contact us with inquiries and questions at